https://www.nasdaq.com/press-release/arcturus-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-1
https://www.nasdaq.com/press-release/arcturus-therapeutics-reports-new-data-and-provides-additional-updates-from-arct-154
https://www.nasdaq.com/press-release/arcturus-therapeutics-appoints-jing-marantz-m.d.-ph.d.-m.b.a.-to-its-board-of
https://www.nasdaq.com/press-release/arcturus-therapeutics-to-participate-in-piper-sandler-33rd-annual-healthcare
https://www.nasdaq.com/press-release/arcturus-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-0
https://www.nasdaq.com/press-release/arcturus-therapeutics-announces-third-quarter-2021-financial-update-and-pipeline
https://www.nasdaq.com/press-release/arcturus-therapeutics-to-report-third-quarter-2021-financial-results-and-provide
https://www.nasdaq.com/press-release/arcturus-therapeutics-announces-leadership-appointments-2021-10-21
https://www.nasdaq.com/press-release/arcturus-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-2021
https://www.nasdaq.com/press-release/arcturus-therapeutics-announces-approval-from-vietnam-ministry-of-health-to-proceed-0
https://www.nasdaq.com/press-release/arcturus-therapeutics-announces-meeting-with-president-of-vietnam-and-ceo-of-vingroup
https://www.nasdaq.com/press-release/arcturus-therapeutics-announces-approval-from-vietnam-ministry-of-health-to-proceed
https://www.nasdaq.com/press-release/arcturus-therapeutics-to-participate-in-citis-16th-annual-biopharma-virtual
https://www.nasdaq.com/press-release/arcturus-therapeutics-to-present-at-upcoming-investor-and-scientific-conferences-3
https://www.nasdaq.com/press-release/thinking-about-buying-stock-in-arcturus-therapeutics-imv-inc-fisker-oramed
https://www.nasdaq.com/press-release/arcturus-therapeutics-announces-second-quarter-2021-financial-results-and-mrna
https://www.nasdaq.com/press-release/arcturus-announces-approval-of-singapore-clinical-trial-application-to-advance-arct
https://www.nasdaq.com/press-release/vingroup-collaborates-with-arcturus-therapeutics-to-establish-a-manufacturing
https://www.nasdaq.com/press-release/arcturus-announces-approval-of-a-clinical-trial-application-to-advance-arct-154-a
https://www.nasdaq.com/press-release/arcturus-therapeutics-collaborates-with-vingroup-to-establish-manufacturing-facility
https://www.nasdaq.com/press-release/arcturus-announces-regulatory-approval-to-proceed-with-phase-2-study-of-arct-810-mrna
https://www.nasdaq.com/press-release/arcturus-therapeutics-to-report-second-quarter-2021-financial-results-and-provide
https://www.nasdaq.com/press-release/arcturus-therapeutics-to-present-at-upcoming-investor-and-scientific-conferences-2
https://www.nasdaq.com/press-release/arcturus-therapeutics-to-present-at-upcoming-investor-and-scientific-conferences-1
https://www.nasdaq.com/press-release/primordial-genetics-grants-arcturus-therapeutics-exclusive-license-of-an-rna
https://www.nasdaq.com/press-release/arcturus-therapeutics-announces-first-quarter-2021-company-overview-and-financial
https://www.nasdaq.com/press-release/arcturus-therapeutics-to-report-first-quarter-2021-financial-results-and-provide
https://www.nasdaq.com/press-release/arcturus-therapeutics-to-present-at-upcoming-investor-and-scientific-conferences-2021
https://www.nasdaq.com/press-release/arcturus-therapeutics-announces-fourth-quarter-and-full-year-2020-financial-results
https://www.nasdaq.com/press-release/arcturus-therapeutics-acquires-exclusive-license-to-mrna-manufacturing-technology
https://www.nasdaq.com/press-release/arcturus-therapeutics-to-report-fourth-quarter-and-year-end-2020-financial-results
https://www.nasdaq.com/press-release/arcturus-therapeutics-to-present-at-upcoming-investor-conferences-2021-02-11
https://www.nasdaq.com/press-release/arcturus-therapeutics-to-present-at-upcoming-investor-conference-2021-01-06
https://www.nasdaq.com/press-release/arcturus-therapeutics-receives-fda-allowance-to-proceed-with-phase-2-study-of-arct
https://www.nasdaq.com/press-release/arcturus-therapeutics-to-advance-arct-032-an-aerosolized-lunarr-mrna-based
https://www.nasdaq.com/press-release/arcturus-therapeutics-received-approval-from-singapore-health-sciences-authority-to
https://www.nasdaq.com/press-release/arcturus-therapeutics-announces-pricing-of-%24150-million-public-offering-of-common
https://www.nasdaq.com/press-release/arcturus-therapeutics-announces-proposed-public-offering-of-common-stock-2020-12-07
https://www.nasdaq.com/press-release/arcturus-therapeutics-announces-initiation-of-dosing-arct-810-in-patients-with
https://www.nasdaq.com/press-release/arcturus-therapeutics-to-present-at-upcoming-investor-conference-2020-11-30
https://www.nasdaq.com/press-release/arcturus-therapeutics-announces-third-quarter-2020-financial-results-and-positive
https://www.nasdaq.com/press-release/arcturus-therapeutics-announces-positive-interim-arct-021-lunar-cov19-phase-1-2-study
https://www.nasdaq.com/press-release/arcturus-therapeutics-to-present-at-upcoming-investor-and-scientific-conferences-0
https://www.nasdaq.com/press-release/arcturus-therapeutics-to-report-third-quarter-2020-financial-results-and-provide
https://www.nasdaq.com/press-release/arcturus-therapeutics-announces-completion-of-first-three-dose-escalation-cohorts-in
https://www.nasdaq.com/press-release/arcturus-therapeutics-to-present-at-guggenheims-vaccines-and-infectious-diseases
https://www.nasdaq.com/press-release/arcturus-therapeutics-to-present-at-upcoming-investor-and-scientific-conferences-2020
https://www.nasdaq.com/press-release/arcturus-therapeutics-announces-preclinical-publication-of-its-covid-19-vaccine
https://www.nasdaq.com/press-release/ld-micro-360-companies-set-to-present-this-week-2020-08-31
https://www.nasdaq.com/press-release/arcturus-therapeutics-executes-definitive-supply-agreement-with-the-israeli-ministry
https://www.nasdaq.com/press-release/arcturus-therapeutics-announces-that-it-has-initiated-dosing-of-its-covid-19-starrtm
https://www.nasdaq.com/press-release/arcturus-therapeutics-announces-second-quarter-2020-financial-results-and-provides-a
https://www.nasdaq.com/press-release/arcturus-therapeutics-appoints-lance-kurata-as-chief-legal-officer-2020-08-06
https://www.nasdaq.com/press-release/arcturus-therapeutics-to-report-second-quarter-2020-financial-results-and-provide
https://www.nasdaq.com/press-release/arcturus-therapeutics-announces-closing-of-public-offering-and-full-exercise-of-0
https://www.nasdaq.com/press-release/arcturus-therapeutics-announces-pricing-of-%24173.0-million-public-offering-of-common
https://www.nasdaq.com/press-release/arcturus-therapeutics-announces-proposed-public-offering-of-common-stock-2020-07-28
https://www.nasdaq.com/press-release/arcturus-therapeutics-announces-agreement-with-israeli-ministry-of-health-to-supply
https://www.nasdaq.com/press-release/arcturus-therapeutics-duke-nus-received-approval-to-proceed-with-phase-1-2-clinical
https://www.nasdaq.com/press-release/arcturus-therapeutics-announces-the-formation-of-its-vaccine-platform-scientific
https://www.nasdaq.com/press-release/arcturus-therapeutics-to-be-added-to-russell-2000r-index-2020-06-29
https://www.nasdaq.com/press-release/arcturus-therapeutics-to-present-at-the-raymond-james-human-health-innovation-virtual
https://www.nasdaq.com/press-release/arcturus-therapeutics-announces-first-healthy-volunteer-dosed-in-phase-1-study-of
https://www.nasdaq.com/press-release/ultragenyx-announces-exercise-of-option-to-purchase-additional-stock-of-arcturus
https://www.nasdaq.com/press-release/arcturus-reports-additional-supportive-preclinical-data-for-its-covid-19-vaccine
https://www.nasdaq.com/press-release/arcturus-therapeutics-announces-first-quarter-2020-financial-results-and-provides-a
https://www.nasdaq.com/press-release/arcturus-therapeutics-to-report-first-quarter-2020-financial-results-and-provide-a
https://www.nasdaq.com/press-release/arcturus-therapeutics-and-catalent-announce-partnership-to-manufacture-mrna-based
https://www.nasdaq.com/press-release/arcturus-reports-positive-preclinical-data-for-its-covid-19-vaccine-candidate-2020-04
https://www.nasdaq.com/press-release/arcturus-therapeutics-announces-closing-of-public-offering-and-full-exercise-of
https://www.nasdaq.com/press-release/arcturus-therapeutics-announces-pricing-of-%2470.0-million-public-offering-of-common
https://www.nasdaq.com/press-release/arcturus-therapeutics-announces-proposed-public-offering-of-common-stock-2020-04-15
https://www.nasdaq.com/press-release/arcturus-therapeutics-announces-allowance-of-ind-approval-of-clinical-trial
https://www.nasdaq.com/press-release/arcturus-therapeutics-announces-clinical-trial-timeline-for-its-covid-19-vaccine-2020
https://www.nasdaq.com/press-release/arcturus-covid-19-vaccine-to-benefit-from-duke-nus-genetic-correlation-system-2020-03
https://www.nasdaq.com/press-release/arcturus-therapeutics-reports-fourth-quarter-and-year-end-2019-financial-results-2020
https://www.nasdaq.com/press-release/arcturus-therapeutics-and-duke-nus-medical-school-partner-to-develop-a-coronavirus
https://www.nasdaq.com/press-release/arcturus-therapeutics-to-report-fourth-quarter-and-year-end-2019-financial-results
https://www.nasdaq.com/press-release/arcturus-therapeutics-to-present-at-two-investor-conferences-in-march-2020-02-19
https://www.nasdaq.com/press-release/arcturus-therapeutics-appoints-steve-hughes-m.d.-as-chief-development-officer-2020-01
https://www.nasdaq.com/press-release/arcturus-therapeutics-to-present-at-the-investor-summit-on-december-17th-in
https://www.nasdaq.com/press-release/arcturus-therapeutics-announces-third-quarter-financial-results-and-provides
https://www.nasdaq.com/press-release/arcturus-therapeutics-expands-platform-with-starr-technologytm-2019-11-07
https://www.nasdaq.com/press-release/arcturus-therapeutics-to-report-corporate-overview-and-financial-results-on-november
